Walder Wyss advised DiNAQOR in its collaboration and license agreement with BioMarin

BioMarin Pharmaceutical announced that the company has entered into a preclinical collaboration and license agreement with DiNAQOR, a gene therapy platform company headquartered in Pfäffikon, to develop novel gene therapies to treat rare genetic cardiomyopathies. DiNAQOR will receive an undisclosed upfront payment and is eligible to receive development, regulatory and commercial milestones on product sales in addition to tiered royalties on worldwide sales.

The team

Walder Wyss advised DiNAQOR on all legal aspects of the transaction, including corporate, IP and life science issues. The team was led by partner Hans Rudolf Trüeb (ip/it) and included senior associate Marion Bähler (corporate/m&a) and associate Florian C. Roth (ip/it).
Walder Wyss advised DiNAQOR in its collaboration and license agreement with BioMarin



Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website www.lcpublishinggroup.com

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2022 © All rights Reserved. Design by Origami Creative Studio


Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram